Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type
- PMID: 21292041
- DOI: 10.1016/j.arr.2011.01.003
Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type
Abstract
Behavioral and psychological symptoms of dementia (BPSD) include agitation, aberrant motor behavior, anxiety, elation, irritability, depression, apathy, disinhibition, delusions, hallucinations, and sleep or appetite impairment. These symptoms have adverse consequences for patients and caregivers, such as greater impairment in activities of daily living, worsening quality of life and earlier institutionalization. While the etiology of BPSD has not been clearly delineated, studies assessing the benefits of acetylcholinesterase inhibitors on BPSD suggest that some of the neuropsychiatric symptoms of dementia such as agitation, apathy and psychosis may represent a specific central cholinergic deficiency syndrome. Biochemical and neuroimaging studies of BPSD in Alzheimer's patients support these pharmacological data. This review discusses the literature describing the association between cholinergic deficiency and manifestations of BPSD.
Copyright © 2011 Elsevier B.V. All rights reserved.
Similar articles
-
Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients.Psychiatry Clin Neurosci. 2005 Jun;59(3):274-9. doi: 10.1111/j.1440-1819.2005.01371.x. Psychiatry Clin Neurosci. 2005. PMID: 15896220 Clinical Trial.
-
Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community.Dement Geriatr Cogn Disord. 2007;23(4):219-24. doi: 10.1159/000099472. Epub 2007 Feb 9. Dement Geriatr Cogn Disord. 2007. PMID: 17299264
-
The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.Int J Clin Pract Suppl. 2002 Jun;(127):20-36. Int J Clin Pract Suppl. 2002. PMID: 12139365 Review.
-
Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease.Alzheimer Dis Assoc Disord. 1997;11 Suppl 4:S1-9. Alzheimer Dis Assoc Disord. 1997. PMID: 9339266 Review.
-
Relationship between dementia severity and behavioural and psychological symptoms in early-onset Alzheimer's disease.Psychogeriatrics. 2015 Dec;15(4):242-7. doi: 10.1111/psyg.12108. Epub 2015 Mar 3. Psychogeriatrics. 2015. PMID: 25737233
Cited by
-
Design, synthesis and biological evaluation of novel N-phosphorylated and O-phosphorylated tacrine derivatives as potential drugs against Alzheimer's disease.J Enzyme Inhib Med Chem. 2022 Dec;37(1):1012-1022. doi: 10.1080/14756366.2022.2045591. J Enzyme Inhib Med Chem. 2022. PMID: 35361039 Free PMC article.
-
Cholinergic Antagonists and Behavioral Disturbances in Neurodegenerative Diseases.Int J Mol Sci. 2023 Apr 7;24(8):6921. doi: 10.3390/ijms24086921. Int J Mol Sci. 2023. PMID: 37108085 Free PMC article. Review.
-
Basal forebrain volume is associated with cortical amyloid burden in cognitively unimpaired older adults at varying genetic risk for Alzheimer's disease.bioRxiv [Preprint]. 2025 Jun 30:2025.05.28.656557. doi: 10.1101/2025.05.28.656557. bioRxiv. 2025. PMID: 40501985 Free PMC article. Preprint.
-
The Efficacy of High- or Low-Frequency Transcranial Magnetic Stimulation in Alzheimer's Disease Patients with Behavioral and Psychological Symptoms of Dementia.Adv Ther. 2022 Jan;39(1):286-295. doi: 10.1007/s12325-021-01964-8. Epub 2021 Oct 29. Adv Ther. 2022. PMID: 34716559
-
Therapeutic Potential of Multifunctional Tacrine Analogues.Curr Neuropharmacol. 2019;17(5):472-490. doi: 10.2174/1570159X16666180412091908. Curr Neuropharmacol. 2019. PMID: 29651948 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical